Literature DB >> 11836387

Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.

Ming Ye1, Christopher S Morello, Deborah H Spector.   

Abstract

We previously showed that intradermal immunization with plasmids expressing the murine cytomegalovirus (MCMV) protein IE1-pp89 or M84 protects against viral challenge and that coimmunization has a synergistic protective effect (C. S. Morello, L. D. Cranmer, and D. H. Spector, J. Virol. 74:3696-3708, 2000). Using an intracellular gamma interferon cytokine staining assay, we have now characterized the CD8+ T-cell response after DNA immunization with pp89, M84, or pp89 plus M84. The pp89- and M84-specific CD8+ T-cell responses peaked rapidly after three immunizations. DNA immunization and MCMV infection generated similar levels of pp89-specific CD8+ T cells. In contrast, a significantly higher level of M84-specific CD8+ T cells was elicited by DNA immunization than by MCMV infection. Fusion of ubiquitin to pp89 enhanced the CD8+ T-cell response only under conditions where vaccination was suboptimal. Three immunizations with either pp89, M84, or pp89 plus M84 DNA also provided significant protection against MCMV infection for at least 6 months, with the best protection produced by coimmunization. A substantial percentage of antigen-specific CD8+ T cells remained detectable, and they responded rapidly to the MCMV challenge. These results underscore the importance of considering antigens that do not appear to be highly immunogenic during infection as DNA vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836387      PMCID: PMC153826          DOI: 10.1128/jvi.76.5.2100-2112.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells.

Authors:  M K Slifka; F Rodriguez; J L Whitton
Journal:  Nature       Date:  1999-09-02       Impact factor: 49.962

2.  Intracellular staining for TNF and IFN-gamma detects different frequencies of antigen-specific CD8(+) T cells.

Authors:  V P Badovinac; J T Harty
Journal:  J Immunol Methods       Date:  2000-04-21       Impact factor: 2.303

Review 3.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization.

Authors:  D E Hassett; J Zhang; M Slifka; J L Whitton
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates.

Authors:  R Holtappels; J Podlech; G Geginat; H P Steffens; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

6.  Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation.

Authors:  J Podlech; R Holtappels; N Wirtz; H P Steffens; M J Reddehase
Journal:  J Gen Virol       Date:  1998-09       Impact factor: 3.891

7.  The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells.

Authors:  R Holtappels; D Thomas; J Podlech; G Geginat; H P Steffens; M J Reddehase
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

8.  In vivo replication, latency, and immunogenicity of murine cytomegalovirus mutants with deletions in the M83 and M84 genes, the putative homologs of human cytomegalovirus pp65 (UL83).

Authors:  C S Morello; L D Cranmer; D H Spector
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

9.  DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

Authors:  G Delogu; A Howard; F M Collins; S L Morris
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

10.  Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).

Authors:  C S Morello; L D Cranmer; D H Spector
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

View more
  20 in total

Review 1.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

2.  Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.

Authors:  Bala V K Karuturi; Shailendra B Tallapaka; Pravin Yeapuri; Stephen M Curran; Sam D Sanderson; Joseph A Vetro
Journal:  Mol Pharm       Date:  2017-04-03       Impact factor: 4.939

3.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 4.  Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection.

Authors:  Stefan Ebert; Jürgen Podlech; Dorothea Gillert-Marien; Kerstin M Gergely; Julia K Büttner; Annette Fink; Kirsten Freitag; Doris Thomas; Matthias J Reddehase; Rafaela Holtappels
Journal:  Med Microbiol Immunol       Date:  2012-09-13       Impact factor: 3.402

5.  Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting.

Authors:  Marcus-Folker Pahl-Seibert; Markus Juelch; Jürgen Podlech; Doris Thomas; Petra Deegen; Matthias J Reddehase; Rafaela Holtappels
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

7.  Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo.

Authors:  Luka Cicin-Sain; Wolfram Brune; Ivan Bubic; Stipan Jonjic; Ulrich H Koszinowski
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.

Authors:  Ming Ye; Christopher S Morello; Deborah H Spector
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination.

Authors:  Rafaela Holtappels; Christian O Simon; Michael W Munks; Doris Thomas; Petra Deegen; Birgit Kühnapfel; Torsten Däubner; Simone F Emde; Jürgen Podlech; Natascha K A Grzimek; Silke A Oehrlein-Karpi; Ann B Hill; Matthias J Reddehase
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

10.  Anaplasma marginale type IV secretion system proteins VirB2, VirB7, VirB11, and VirD4 are immunogenic components of a protective bacterial membrane vaccine.

Authors:  Eric L Sutten; Junzo Norimine; Paul A Beare; Robert A Heinzen; Job E Lopez; Kaitlyn Morse; Kelly A Brayton; Joseph J Gillespie; Wendy C Brown
Journal:  Infect Immun       Date:  2010-01-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.